An update to "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma” is now available.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum.
Rapid Update v1.4 Summary
- Based on the FDA approvals and practice-changing data listed below, updates have been made to the guideline's narrative text, recommendations, and Table 4.
- The FDA granted approval of denileukin diftitox-cxdl for the treatment of patients with stage 1 to 3 relapsed/refractory cutaneous TCL after at least 1 prior systemic therapy in August 2024.
- The FDA granted accelerated approval of epcoritamab for adult patients with relapsed or refractory FL after two or more lines of systemic therapy in June 2024.
- The FDA granted approval of lisocabtagene maraleucel for adult patients with relapsed or refractory mantle cell lymphoma MCL who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi) in May 2024.
- The FDA granted accelerated approval of lisocabtagene maraleucel for adults with relapsed or refractory FL who have received two or more prior lines of systemic therapy in May 2024.
- The FDA granted accelerated approval of lisocabtagene maraleucel for adult patients with relapsed or refractory CLL or SLL who have received at least 2 prior lines of therapy, including a BTKi and a B-cell lymphoma 2 (BCL-2) inhibitor in March 2024.
- The FDA granted accelerated approval of zanubrutinib with obinutuzumab for relapsed or refractory FL after two or more lines of systemic therapy in March 2024.
- The FDA granted accelerated approval of glofitamab for relapsed or refractory diffuse large B-cell lymphoma DLBCL, not otherwise specified (NOS) or LBCL arising from FL, after two or more lines of systemic therapy in June 2023.
- The FDA granted accelerated approval of epcoritamab for relapsed or refractory DLBCL NOS, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBL) after two or more lines of systemic therapy in May 2023.
- The FDA granted approval of polatuzumab vedotin with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated DLBCL, NOS or HGBL and who have an International Prognostic Index (IPI) score of 2 or greater in April 2023.
- The FDA granted accelerated approval of mosunetuzumab for adult patients with relapsed or refractory FL after two or more lines of systemic therapy in December 2022.
- Data have been reported on the safety and efficacy of lenalidomide + obinutuzumab for relapsed or refractory FL and marginal zone lymphoma.
- Data have been reported on the safety and efficacy of nivolumab + AVD for patients with Hodgkin lymphoma.
- Data have been reported on the safety and efficacy of nivolumab + chemotherapy and pembrolizumab + chemotherapy for patients with relapsed or refractory Hodgkin lymphoma.
- Data have been reported on the safety and efficacy of BV-nivolumab for the treatment of R/R PMBCL.
How to View the Living Guideline Rapid Update
Through the use of an innovative technology, rapid updates are swiftly integrated into our existing published guidelines in a clear and concise manner. An overlay system highlights affected content and provides new text reflecting the updated Expert Panel guidance as well as important supporting information, data, and references, as applicable. These rapid updates show the progression of the changes by using a version numbering system that accompanies each new posted update.
- View Update v1.4 as an overlay to the original publication in JITC
For More Information
- SITC Lymphoma CPG Webpage – Overview of all available updates and companion guideline educational offerings for this guideline
- SITC Guidelines Program – Listing of all published guidelines in the SITC CPG catalogue and more about the SITC Living Guidelines rapid updates
- Follow us on social media – #SITCGuidelines on “X” and LinkedIn
- Questions – Contact a member of the SITC guideline development staff at scientificresources@sitcancer.org